Novo Nordisk's Phase 3 ZEUS Trial for IL-6 Inhibitor Ziltivekimab Fails, Halting Cardiovascular Expansion Plans
Phase 3 Trial Failure for IL-6 Targeted Therapy Ziltivekimab
Novo Nordisk's interleukin-6 (IL-6) targeting monoclonal antibody, ziltivekimab, failed to achieve its primary endpoint in the Phase 3 ZEUS trial. The trial, which involved over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and systemic inflammation, did not demonstrate a reduction in major adverse cardiovascular events (MACE) compared to placebo. While the drug showed a reduction in high-sensitivity C-reactive protein (hsCRP) levels, a marker of inflammation, the hazard ratio of 0.99 indicated no significant clinical benefit in reducing cardiovascular risk. This outcome represents a fundamental setback for the mechanism of inhibiting IL-6 ligands to treat cardiovascular inflammation.
Solidified Competitive Landscape Dominated by Farxiga and Jardiance
This failure is expected to further solidify the market landscape, currently dominated by existing standard-of-care treatments, in the SGLT2 inhibitor market, which is projected to reach approximately $18 billion (USD) by 2025 and exceed $30 billion (USD) by 2030. AstraZeneca's Farxiga and Eli Lilly's Jardiance currently hold a strong position in the cardiology market for chronic kidney disease (CKD) and cardiovascular indications. Similar to the limitations previously observed with Novartis's Ilaris, developing cardiovascular therapies through anti-inflammatory mechanisms faces significant challenges. This development is likely to further strengthen the position of existing competitive treatments such as statins and low-dose colchicine (LODOCO).
Setback for Diversification Strategy Beyond Obesity and Diabetes
The failure of the ZEUS trial represents a significant setback for Novo Nordisk's strategy to reduce its reliance on GLP-1 receptor agonists like semaglutide and expand into cardiovascular and renal disease areas. Market analysts had anticipated that ziltivekimab could achieve peak annual sales of $3 billion (USD) in the chronic kidney disease (CKD) patient population. The company will reflect a non-cash impairment charge in its Q3 2026 results, and the timeline for securing new growth drivers beyond the obesity segment will inevitably be delayed.
Pressure for Follow-up Trials and M&A Activity
Novo Nordisk plans to release the results of the HERMES trial, which targets heart failure patients, and the ARTEMIS trial, which targets acute myocardial infarction patients, in the first half of 2027. However, due to the failure of the initial Phase 3 trial, market experts are highly skeptical about the potential success of these follow-up trials. If these remaining trials also fail, Novo Nordisk will need to completely reassess its cardiovascular pipeline. Consequently, to overcome the risk of over-reliance on obesity and diabetes treatments, the company will face increased pressure to pursue large-scale mergers and acquisitions (M&A) to acquire external pipelines.
Novo Nordisk's (NVO) Phase 3 ZEUS trial failure for ziltivekimab, for which the company paid upfront payments of $725 million and milestone payments of $1.375 billion, totaling $2.1 billion, has prematurely eliminated the potential for peak annual sales of $3 billion. This failure is expected to further solidify the market position of existing SGLT2 inhibitor therapies, such as AstraZeneca's Farxiga and Eli Lilly's Jardiance, in the chronic kidney disease and cardiovascular market, which is projected to reach $18 billion by 2025. Furthermore, it has cast doubt on the potential success of the follow-up Phase 3 trials, HERMES and ARTEMIS, which are expected to report topline results in the first half of 2027, thereby significantly hindering Novo Nordisk's strategy to diversify its portfolio into the cardiovascular area. As a result, Novo Nordisk will face increased pressure to pursue large-scale mergers and acquisitions (M&A) targeting biotechnology companies in the cardiovascular and metabolic disease fields to reduce its extreme dependence on obesity and diabetes treatments.